Details for Patent: 9,937,164
✉ Email this page to a colleague
Which drugs does patent 9,937,164 protect, and when does it expire?
Patent 9,937,164 protects BRIXADI and is included in one NDA.
This patent has one hundred and fifteen patent family members in thirty-three countries.
Summary for Patent: 9,937,164
| Title: | Opioid formulations |
| Abstract: | A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided. |
| Inventor(s): | Tiberg Fredrik, Harwigsson Ian, Johnsson Markus |
| Assignee: | Camurus AB |
| Application Number: | US14416421 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 9,937,164
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-001 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-002 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-003 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-004 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-005 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-006 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,937,164
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E401054 | ⤷ Sign Up | |||
| Austria | E462409 | ⤷ Sign Up | |||
| Austria | E501710 | ⤷ Sign Up | |||
| Australia | 2005249274 | ⤷ Sign Up | |||
| Australia | 2005324794 | ⤷ Sign Up | |||
| Australia | 2010202794 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
